Currently, Nektar Therapeutics [NKTR] is trading at $0.91, up 1.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The NKTR shares have gain 10.89% over the last week, with a monthly amount glided 1.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on March 14, 2025, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $6 for it. Previously, B. Riley Securities started tracking the stock with Buy rating on January 08, 2025, and set its price target to $4. On December 10, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $6.50 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $7 on November 04, 2024. Rodman & Renshaw started tracking with a Buy rating for this stock on June 28, 2024, and assigned it a price target of $2.
This stock has fluctuated between a low of $0.65 and a high of $1.93 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $0.91 at the most recent close of the market. An investor can expect a potential return of 1740.66% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Trailing Twelve Months sales for Nektar Therapeutics [NASDAQ:NKTR] were 98.43M which represents 22.15% growth. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -1.46%, Pretax Profit Margin comes in at -1.81%, and Net Profit Margin reading is -1.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -1.74 and Total Capital is -0.57. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8716 points at the first support level, and at 0.8338 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9555, and for the 2nd resistance point, it is at 1.0016.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nektar Therapeutics [NASDAQ:NKTR] is 4.26. On the other hand, the Quick Ratio is 4.26, and the Cash Ratio is 0.45. Considering the valuation of this stock, the price to sales ratio is 1.70, the price to book ratio is 3.43.
Transactions by insiders
Recent insider trading involved Zalevsky Jonathan, Chief R&D Officer, that happened on Feb 19 ’25 when 10300.0 shares were sold. Chief Legal Officer, Wilson Mark Andrew completed a deal on Feb 19 ’25 to sell 11040.0 shares. Meanwhile, President & CEO ROBIN HOWARD W sold 23774.0 shares on Feb 19 ’25.
